IPOs and the New FDA
This article was originally published in RPM Report
Executive Summary
Ironwood Pharmaceuticals and Anthera Pharmaceuticals tested the public offering market in early 2010. The two companies share a positive reading on a thaw in the freeze on public financings, but they show different attitudes on the nature of the regulatory climate. To Ironwood, past regualtory difficulties for other companies are an opportunity. Ironwood does not see much of a threat from new FDA safety tools. Anthera sees the threat but says it has a plan to navigate the new authorities.